Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis
Lucia Moiola, Paulus Rommer, Uwe K. Zettl
Current Opinion in Neurology (2020) Vol. 33, Iss. 3, pp. 286-294
Closed Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Vaccination and immunotherapies in neuroimmunological diseases
Alexander Winkelmann, Micha Loebermann, Michael Barnett, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 5, pp. 289-306
Open Access | Times Cited: 46
Plant-based production of an orally active cyclotide for the treatment of multiple sclerosis
Mark A. Jackson, Jing Xie, Linh T. T. Nguyen, et al.
Transgenic Research (2023) Vol. 32, Iss. 1-2, pp. 121-133
Open Access | Times Cited: 15
Genetic, Environmental and Lifestyle Determinants of Accelerated Telomere Attrition as Contributors to Risk and Severity of Multiple Sclerosis
Michael Hecker, Jan Bühring, Brit Fitzner, et al.
Biomolecules (2021) Vol. 11, Iss. 10, pp. 1510-1510
Open Access | Times Cited: 29
Oxymatrine ameliorates experimental autoimmune encephalomyelitis by rebalancing the homeostasis of gut microbiota and reducing blood-brain barrier disruption
Mingliang Zhang, Weixia Li, Xiaoyan Wang, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 12
Open Access | Times Cited: 11
Palliative care need and quality of life mediated by psychological distress in neurologic diseases
Lily Man Lee Chan, Edmond Pui Hang Choi, Wwt Lam, et al.
Journal of Pain and Symptom Management (2025)
Open Access
Trauma Burden Affected People with Multiple Sclerosis During SARS-CoV-2 Pandemic
Felicita Heidler, Michael Hecker, Niklas Frahm, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 8, pp. 2665-2665
Open Access
Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry
Niklas Frahm, David Ellenberger, Alexander Stahmann, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 3
Vaccination status and self-reported side effects after SARS-CoV-2 vaccination in relation to psychological and clinical variables in patients with multiple sclerosis
Katja Burian, Felicita Heidler, Niklas Frahm, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care
Kris Oliver Jalusic, David Ellenberger, Paulus Rommer, et al.
Multiple Sclerosis Journal (2021) Vol. 27, Iss. 12, pp. 1852-1863
Open Access | Times Cited: 23
Prevalence and Severity of Potential Drug–Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy
Paula Bachmann, Niklas Frahm, Jane Louisa Debus, et al.
Pharmaceutics (2022) Vol. 14, Iss. 3, pp. 592-592
Open Access | Times Cited: 14
Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis
Hans‐Peter Hartung, Sven G. Meuth, Deborah Miller, et al.
Current Opinion in Neurology (2021) Vol. 34, Iss. 4, pp. 598-603
Closed Access | Times Cited: 20
Treatment Options in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
Paulus Rommer, Uwe K. Zettl
Current Pharmaceutical Design (2021) Vol. 28, Iss. 6, pp. 428-436
Closed Access | Times Cited: 16
Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple Sclerosis
Michael Hecker, Niklas Frahm, Uwe K. Zettl
Pharmaceutics (2023) Vol. 16, Iss. 1, pp. 3-3
Open Access | Times Cited: 6
Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets
Ralf Gold, Gerd Fätkenheuer, Hans‐Peter Hartung, et al.
Therapeutic Advances in Neurological Disorders (2021) Vol. 14
Open Access | Times Cited: 14
Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT
Peter Rieckmann, Tjalf Ziemssen, Iris-Katarina Penner, et al.
Advances in Therapy (2022) Vol. 39, Iss. 6, pp. 2749-2760
Open Access | Times Cited: 7
Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic
Felicita Heidler, Julia Baldt, Niklas Frahm, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 6
Vaccination frequency in people newly diagnosed with multiple sclerosis
Sonia Darvishi, Ewan Donnachie, Christiane Gasperi, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 14, pp. 1831-1840
Open Access | Times Cited: 3
General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis
Barbara Streckenbach, Julia Baldt, Felicita Heidler, et al.
Vaccine (2022) Vol. 40, Iss. 23, pp. 3236-3243
Open Access | Times Cited: 5
Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis
Silvan Elias Langhorst, Niklas Frahm, Michael Hecker, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 5, pp. 677-677
Open Access | Times Cited: 5
Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
Oliver Neuhaus, Wolfgang Köhler, Florian Then Bergh, et al.
Biomolecules (2021) Vol. 11, Iss. 3, pp. 393-393
Open Access | Times Cited: 7
Vaccination Setting of Patients with Autoimmune Diseases in Times of Severe Acute Respiratory Syndrome Coronavirus Type 2 Pandemic Using the Example of Multiple Sclerosis Patients: A Longitudinal Multicenter Study
Felicita Heidler, Julia Baldt, Niklas Frahm, et al.
European Neurology (2021) Vol. 85, Iss. 2, pp. 104-111
Open Access | Times Cited: 7
Headache in Multiple Sclerosis - Pharmacological Aspects
Marcel Gebhardt, Peter Kropp, Frank Hoffmann, et al.
Current Pharmaceutical Design (2021) Vol. 28, Iss. 6, pp. 445-453
Closed Access | Times Cited: 5
Literaturverzeichnis zum Titel: Zettl/Sieb: Diagnostik und Therapie neurologischer Erkrankungen, 6.A. 2024

Elsevier eBooks (2024), pp. e1-e123
Closed Access
Polypharmazie
Niklas Frahm, Michael Hecker, Uwe K. Zettl
Elsevier eBooks (2024), pp. 659-667
Closed Access
Immunmediierte Erkrankungen des Nervensystems
Uwe K. Zettl, Jörn Peter Sieb
Elsevier eBooks (2024), pp. 47-109
Closed Access
Page 1 - Next Page

Scroll to top